UNSPSC 51171831: Cipropride

This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0D2VUO6DCN. European Medicines Agency schedules Cipropride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07472MIG. Cipropride generally arises in the molecular formula C17H25N3O4S.

UNSPSC 51171831 Cipropride, a Commodity code, describes pharmaceutical active ingredients and finished formulations purchased by state and local government entities, particularly for offender drug screening, public health pharmacy benefit programs, and cooperative purchasing networks serving multiple jurisdictions. State and local agencies buy cipropride and related pharmaceutical products through direct-purchase contracts with manufacturers, cooperative purchasing vehicles managed by state procurement offices, and specialized contracts for correctional and health services. The issuing bodies include county correction departments (supervising probation and parole populations), state health and human services agencies managing pharmacy benefits and Medicaid formularies, and multistate cooperative purchasing alliances coordinating procurement for participating states and local governments across multiple jurisdictions.

Recent activity clusters in Texas and Minnesota. Collin County Community Supervision and Corrections Department in Texas issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year initial term with optional renewals, encompassing approximately 25,031 tests annually across multiple panel configurations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with products to be available through authorized wholesalers by May 15, 2026 and contract effectiveness on July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs, indicating the state's intent to develop more formal procurement specifications before issuing a subsequent RFP.